China Challenges the West in Stem-Cell Research
By Susan Brown,
The Chronicle of Higher Education
| 04. 10. 2007
In 1983, Sheng Huizhen did what many of China's brightest students do: She left to pursue research opportunities unavailable to her at home, first in Australia and then in the United States. Sixteen years later, in search of greater scientific freedom, she migrated again. This time she headed back to China. As a researcher who studies embryonic stem cells, Ms. Sheng found the climate in the United States limiting. Although she landed a postdoctoral fellowship at the National Institutes of Health, where she worked her way up to a permanent staff position, federal policy at the time barred her from using human embryos or the cells derived from them.
China, however, embraced Ms. Sheng's work. The city of Shanghai in 1999 offered her $875,000 to set up a new center at her alma mater, Shanghai Jiao Tong University, to study embryonic stem cells. She now directs a group of more than 50 people who are working on several lines of research, seeking to make cells useful for treating disease.
Restrictive policies and a frosty cultural climate in the United States...
Related Articles
By Emily Mullin, Wired | 04.23.2026
A STARTUP OUT of Utah, Paterna Biosciences, says it has successfully grown functional human sperm in a lab and used the sperm to make visibly healthy-looking embryos. The technique could eventually help men with certain types of infertility have biological children...
By Peter Ward, Slate | 03.30.2026
I’m in a cramped examination room at a clinic in Panama City. The lights are dim, and calming classical music plays from built-in speakers. A nurse has injected a dose of stem cells into Kenneth Scott through an IV in...
By David Jensen, The California Stem Cell Report | 03.26.2026
SACRAMENTO, Ca. -- California’s $12 billion stem cell and gene therapy program scored a historic first today, announcing that it had for the first time helped to finance a revolutionary treatment that will now be available to the general public...
By Emily Mullin, Wired | 03.23.2026
As the Trump administration phases out the use of animal experimentation across the federal government, a biotech startup has a bold idea for an alternative to animal testing: nonsentient “organ sacks.”
Bay Area-based R3 Bio has been quietly pitching the...